BridgeBio Pharma Inc vs Alliant Energy Corporation — how do they compare? BridgeBio Pharma Inc trades at $83.9 (market cap $16.61B), while Alliant Energy Corporation trades at $68.56 (market cap $17.69B). The key difference: BridgeBio Pharma Inc and Alliant Energy Corporation are close in size by market cap, and Alliant Energy Corporation pays a 3.14% dividend while BridgeBio Pharma Inc pays none. Which is the better fit depends on your goals.
| BBIO | LNT | |
|---|---|---|
Market Cap | $16.61B | $17.69B |
Sector | Health | Utilities |
52-Week High | $90.17 | $78.03 |
52-Week Low | $47.29 | $63.62 |
Enterprise Value | $18.16B | $29.78B |
Dividend Yield | — | 3.14% |
Signals from Pluang's Aura AI — not financial advice
BridgeBio Pharma (BBIO) trades at $84.48, up 2.03% with bullish technical signals from moving averages. Despite strong revenue growth from $222M in 2024 to $502M in 2025, the company reports significant losses with a -144.39% net margin. Recent FDA acceptance for encaleret in ADH1 and Attruby's commercial expansion in ATTR-CM provide growth catalysts, though cash flow remains negative at -$111M in 2025.
The stock presents high-risk growth potential with 88% analyst buy ratings and $102.20 consensus target, but faces substantial execution risks from ongoing losses and $1.72B debt load. Success hinges on pipeline approvals and Attruby's market penetration, making it suitable for risk-tolerant investors betting on biotech breakthroughs.
LNT trades at $69.37, down 0.22% on the day, with a bearish technical signal from moving averages but oversold RSI readings. The company reported Q2 2026 EPS of $0.65, beating expectations, and maintains strong fundamentals with 18.45% net income margin and 11.14% ROE. Recent news highlights mixed institutional activity and earnings performance influenced by data center demand and cost pressures.
The outlook is balanced with a consensus price target of $77.67 implying upside, supported by earnings beats and a clean energy investment plan. Risks include rising debt levels, cost inflation, and weather-related volatility. Analyst sentiment is positive with no sell ratings, but technical weakness warrants caution near-term.
Trailing returns across standard periods
Latest headlines on both assets
BridgeBio Pharma Inc is involved in identifying advance transformative medicines to treat patients who suffer from Mendelian diseases, which are diseases that arise from defects in a single gene, and cancers with clear genetic drivers. Its product pipeline categories include Mendelian, Genetic Dermatology, Oncology, and Gene therapy.
Read more on BBIO →Alliant Energy is the parent of two regulated utilities, Interstate Power and Light and Wisconsin Power and Light, serving nearly 1 million electricity and natural gas customers and approximately 420,000 natural gas-only customers. Both subsidiaries engage in the generation and distribution of electricity and the distribution and transportation of natural gas. Alliant also owns a 16% interest in American Transmission Co.
Read more on LNT →